These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10348483)

  • 1. The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations.
    Spieker S; Löschmann PA; Klockgether T
    Mov Disord; 1999 May; 14(3):517-9. PubMed ID: 10348483
    [No Abstract]   [Full Text] [Related]  

  • 2. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 3. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 4. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 5. Open pilot trial of ritanserin in parkinsonism.
    Maertens de Noordhout A; Delwaide PJ
    Clin Neuropharmacol; 1986; 9(5):480-4. PubMed ID: 3094935
    [No Abstract]   [Full Text] [Related]  

  • 6. A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
    Nutt J
    Mov Disord; 1999; 14 Suppl 1():74. PubMed ID: 10493408
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).
    Olanow CW; Damier P; Goetz CG; Mueller T; Nutt J; Rascol O; Serbanescu A; Deckers F; Russ H
    Clin Neuropharmacol; 2004; 27(2):58-62. PubMed ID: 15252265
    [No Abstract]   [Full Text] [Related]  

  • 8. [Physiopathology of the dyskinesias induced by L-dopa].
    Grandas F; López-Ariztegui N
    Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):198-200. PubMed ID: 29186084
    [No Abstract]   [Full Text] [Related]  

  • 10. A trial of dextromethorphan in parkinsonian patients with motor response complications.
    Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
    Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
    Onofrj M; Paci C; Thomas A
    J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):605-6. PubMed ID: 9771801
    [No Abstract]   [Full Text] [Related]  

  • 12. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
    Merims D; Ziv I; Djaldetti R; Melamed E
    Lancet; 1999 May; 353(9166):1764-5. PubMed ID: 10347995
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
    Manson AJ; Iakovidou E; Lees AJ
    Mov Disord; 2000 Mar; 15(2):336-7. PubMed ID: 10752589
    [No Abstract]   [Full Text] [Related]  

  • 19. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 20. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.